Navigation Links
MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership
Date:1/3/2012

PLANO, Texas, Jan. 3, 2012 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, today announced it has secured more than $1M in funds from current investors.  The funds will be used to complete a pivotal, Phase 3a human efficacy trial for its lead product, MC-1101.  Concurrently, MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in the territory.

MC-1101 is a proprietary, topically administered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by increasing ocular blood flow in the choroidal vessels. 

"This recent financing and partnership are significant steps forward for MacuCLEAR," commented MacuCLEAR president and CEO, Phillip G. Ralston.  "MC-1101 is on track to pioneering the first treatment for Dry AMD in both the U.S. and the Pacific Rim.  Its unique therapeutic approach, which targets the reduced blood flow that occurs in all AMD patients, has significant advantages over treatments currently on the market and in development."  

MacuCLEAR has an active IND for MC-1101 and has completed a successful Phase Ib/proof of concept human clinical trial which showed that this drug is not only safe and well tolerated by study subjects, MC-1101 eye drops also migrate to the back of the eye through proven pathways and provide unique and effective treatment for AMD at the source of the problem by increasing blood flow in the back of the retina.  MC-1101 is also currently undergoing a nine-month chronic ocular tissue toxicity study in animals, which began in August 2011. 

Mr. Ralston will be available for meetings with potential investors and partners to further discuss company updates during the JP Morgan Healthcare Conference 2012 being held in San Francisco, CA, January 9-12, 2012.

About MacuCLEAR, Inc.
MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal diseases of the eye.  Its lead compound MC-1101 is a novel, topically delivered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by improving ocular blood flow.

The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug.  MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA.  In addition to MC-1101, MacuCLEAR's portfolio includes 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye.

George C.Y. Chiou, Ph.D., who led the development of Timolol, a pioneering treatment for glaucoma, invented this technology at Texas A&M University.

Founded in 2006, MacuCLEAR is a privately held Plano, TX-based company.  For additional information, please visit www.macuclear.com.

About Age-Related Macular Degeneration
AMD is the leading cause for blindness in the world in people 50 and older.  Dry AMD afflicts 90 percent of AMD sufferers and currently has no approved drug treatments. 

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mialach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com

 


'/>"/>
SOURCE MacuCLEAR, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cohera Medical Raises Over $25 Million in Series C Round
2. ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease
3. arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round
4. Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12
5. Bayer Virtual Walk for Hemophilia Raises Awareness and Funds for People With Bleeding Disorders
6. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
7. FRC Praises House Committee for Holding Hearing on Conscience-Violating Obamacare Contraceptive Mandate
8. Perrigo Reports Record Quarterly Revenue and Adjusted Earnings and Raises Full Year Adjusted EPS Guidance
9. goBalto Raises Series A Financing to Advance Cloud-based Health Technologies
10. Grateful Weight Loss Patient Praises Micro Gastric Sleeve Surgery
11. CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):